As mentioned above, MUC1 can regulate glucose metabolism of pancreatic cancer through the HIF-1alpha pathway to induce resistance to gemcitabine, and targeted therapy for MUC1 may enhance the efficacy of gemcitabine for pancreatic cancer [48]. This evidence concerns the gene MUC1 and familial pancreatic carcinoma.